PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26087994-4 2015 AREA COVERED: Rituximab, an mAb directed against a specific antigen expressed on B lymphocytes, CD20 antigen, inducing a premature cell apoptosis became very important in the treatment of membranous glomerulonephritis, steroid-resistant nephrotic syndromes and membranoproliferative glomerulonephritis (MPGN). Steroids 219-226 keratin 20 Homo sapiens 96-100 33628202-3 2020 The anti-CD20 antibody rituximab has shown promising results for treatment of steroid-sensitive nephrotic syndrome. Steroids 78-85 keratin 20 Homo sapiens 9-13 32619893-4 2020 CASE PRESENTATION: We present the case report of a patient with pseudo-tumoral lesion and myelitis refractory to steroids and cyclophosphamide who successfully showed remission after treatment with an anti-CD20 therapy. Steroids 113-121 keratin 20 Homo sapiens 206-210 30564879-2 2020 Although the chimeric anti-CD20 monoclonal antibody rituximab has shown efficacy for frequently relapsing nephrotic syndrome and steroid-dependent nephrotic syndrome, its efficacy for refractory SRNS remains uncertain due to limited data. Steroids 129-136 keratin 20 Homo sapiens 27-31 31365055-7 2019 CASE SUMMARY : Here, we present a case series of six patients with subacute and chronic endomyocardial biopsy-proven CD20+ B-lymphocyte-associated DCMi, where symptomatic heart failure therapy, with or without combined immunosuppressive therapy with steroid-based treatment regime, was insufficient to improve cardiac function. Steroids 250-257 keratin 20 Homo sapiens 117-121 29436729-12 2018 The relatively safe profile of anti-CD20 antibodies supports their use as steroid-sparing agents in children with INS. Steroids 74-81 keratin 20 Homo sapiens 36-40 28415773-5 2017 The presence of CD20+ B cells in renal biopsies during allograft rejection was associated with graft loss and steroid resistance. Steroids 110-117 keratin 20 Homo sapiens 16-20 28415773-7 2017 In conclusion, CD 20+ B cell infiltration during allograft rejection was associated with an increased risk of graft loss and steroid resistance. Steroids 125-132 keratin 20 Homo sapiens 15-20 28366912-2 2017 Rituximab, a chimeric monoclonal anti-CD20 antibody, in low doses has shown efficacy as an adjuvant to reduce the dose of steroids. Steroids 122-130 keratin 20 Homo sapiens 38-42 27789116-3 2017 METHODS AND RESULTS: Here, we report the long-term outcome in two steroid-refractory adolescents with Hashimoto encephalopathy who were treated with rituximab, a monoclonal antibody directed against CD20. Steroids 66-73 keratin 20 Homo sapiens 199-203 33518484-3 2021 The monoclonal antibody anti CD20, Rituximab, is likely to have beneficial effects in cases of steroid-dependent nephrotic syndrome patients with no easy resolution, even when we cannot make a statement about the specific role in the impact. Steroids 95-102 keratin 20 Homo sapiens 29-33 31881522-11 2019 However, the patient was treated with anti-CD20 immunotherapy due to steroid-dependence. Steroids 69-76 keratin 20 Homo sapiens 43-47 28314744-4 2017 The anti-CD20 antibody rituximab has shown promising steroid-sparing properties in clinical trials, but benefits are less convincing in complicated forms of SD-INS. Steroids 53-60 keratin 20 Homo sapiens 9-13 28058267-10 2016 Significantly more CD20-negative patients (49/83, 59.0%) received steroid plus antibody therapy compared with the CD20-positive group (52/133, 39.1%) (P = 0.004). Steroids 66-73 keratin 20 Homo sapiens 19-23 28058267-15 2016 CD20-positive B cell infiltration in renal allograft biopsies with ACR is associated with less steroid resistance and better graft survival. Steroids 95-102 keratin 20 Homo sapiens 0-4 24552605-4 2015 Because of severe thrombocytopenia resistant to immunoglobulins, high-dose steroids, and cyclosporine treatment, anti-cluster of differentiation (CD20) therapy was introduced, with consequent normalization of thrombocytes and weaning off of steroids. Steroids 241-249 keratin 20 Homo sapiens 146-150 24880619-16 2015 The efficacy on the inflammatory component of the disease is comparable to that of steroids and seems to be related with the reduction of peripheral CD20+ lymphocytes. Steroids 83-91 keratin 20 Homo sapiens 149-153 18580460-3 2008 The presence of immature CD20 and mature CD138 plasma cells associate with more aggressive and steroid-recalcitrant graft rejection and portend poor graft outcomes. Steroids 95-102 keratin 20 Homo sapiens 25-29 25741456-1 2015 In the past 10 years, many reports have suggested that rituximab, a chimeric anti-CD20 monoclonal antibody, is effective for children with complicated, frequently relapsing or steroid-dependent nephrotic syndrome (FRNS/SDNS). Steroids 176-183 keratin 20 Homo sapiens 82-86 23144195-1 2013 The treatment of choice in steroid-resistant immune thrombocytopenia is still controversial due to the recent advent of new drugs (anti-CD20 antibodies and thrombopoietin mimetics) that have encouraged a generalized tendency to delay splenectomy. Steroids 27-34 keratin 20 Homo sapiens 136-140 23612383-0 2013 Transient effect of anti-CD20 therapy in a child with 22q11.2 deletion syndrome and severe steroid refractory cytopenias: a case report. Steroids 91-98 keratin 20 Homo sapiens 25-29 22443503-12 2012 Rituximab, an anti-CD20 antibody that specifically depletes B lymphocytes, can be an effective treatment strategy for patients with steroid-refractory, B cell-predominant lymphocytic hypophysitis. Steroids 132-139 keratin 20 Homo sapiens 19-23 21727772-0 2011 Successful treatment of steroid-refractory autoimmune thrombocytopenia associated with Castleman disease with anti-CD-20 antibody (rituximab). Steroids 24-31 keratin 20 Homo sapiens 115-120 20393401-5 2010 The clinical outcomes of CD20 or CD38 B cells were evaluated with late-onset and repeated ACR, steroid resistance, incomplete recovery after rejection treatment, and allograft survival. Steroids 95-102 keratin 20 Homo sapiens 25-29 19460565-0 2009 Orthotopic liver transplantation after successful treatment with anti-CD20 monoclonal antibody (rituximab) for severe steroid-resistant autoimmune hemolytic anemia: a case report. Steroids 118-125 keratin 20 Homo sapiens 70-74 25594706-3 2015 After initiation of therapy with the monoclonal CD20 antibody Rituximab, steroids could be stopped completely and the patient remains in remission. Steroids 73-81 keratin 20 Homo sapiens 48-52 24348405-3 2013 We present a case of IOID that was successfully treated with the anti-CD20 monoclonal antibody rituximab following failed steroid sparing with conventional second-line immunosuppressive agents. Steroids 122-129 keratin 20 Homo sapiens 70-74 22948319-1 2013 BACKGROUND: Rituximab, an anti-CD20 antibody that targets B cells, is a promising agent against steroid-dependent and steroid-resistant nephrotic syndrome in children. Steroids 96-103 keratin 20 Homo sapiens 31-35 22948319-1 2013 BACKGROUND: Rituximab, an anti-CD20 antibody that targets B cells, is a promising agent against steroid-dependent and steroid-resistant nephrotic syndrome in children. Steroids 118-125 keratin 20 Homo sapiens 31-35 21471566-1 2011 OBJECTIVE: To assess the safety and efficacy of the B lymphocyte (anti-CD20) antibody, rituximab, in the treatment of steroid-resistant moderately active ulcerative colitis (UC). Steroids 118-125 keratin 20 Homo sapiens 71-75 18547992-7 2008 Both CD20(+) B cells and CD38(+) cells correlated with poor response of the rejection to steroids. Steroids 89-97 keratin 20 Homo sapiens 5-9 17973121-1 2008 We present the cases of two children with steroid-resistant nephrotic syndrome (SRNS) who were treated with rituximab (anti-CD20 monoclonal antibody). Steroids 42-49 keratin 20 Homo sapiens 124-128 17899207-1 2008 The anti-CD20 antibody rituximab has been used successfully as a rescue therapy in some patients with therapy-refractory steroid-dependent nephrotic syndrome (SDNS), including both primary SDNS with minimal changes on biopsy and recurrent focal segmental glomerulosclerosis (FSGS) after renal transplantation. Steroids 121-128 keratin 20 Homo sapiens 9-13 17532766-12 2007 In conclusion, our experience clearly demonstrates that anti-CD20 monoclonal antibody rituximab is an effective and safe alternative treatment option for idiopathic AIHA, in particular, for steroid-refractory disease. Steroids 190-197 keratin 20 Homo sapiens 61-65 16823816-2 2006 In recent years the anti-CD20 monoclonal antibody rituximab has been used for the therapy of steroid-refractory AIHA and autoimmune thrombocytopenia, either idiopathic or in association with CLL. Steroids 93-100 keratin 20 Homo sapiens 25-29 17264461-2 2007 Treatment with rituximab, a monoclonal antibody against CD20, was associated with remission of symptoms and a steroid sparing effect that persisted for more than 9 months. Steroids 110-117 keratin 20 Homo sapiens 56-60 17198274-1 2006 BACKGROUND: The presence of CD20+ lymphocyte renal allograft infiltrates has been associated with steroid-resistant rejection and poor graft survival. Steroids 98-105 keratin 20 Homo sapiens 28-32 17461736-6 2007 Anti-CD20+ monoclonal antibody therapy (rituximab) aiming at depleting B cells and suppressing antibody production has been used as rescue therapy in some episodes of steroid- and antilymphocyte-resistant humoral rejection. Steroids 167-174 keratin 20 Homo sapiens 5-9 17823525-3 2007 An anti-CD20 monoclonal antibody (rituximab) was proposed because of resistance to high-dose steroids and other immunosuppressive agents. Steroids 93-101 keratin 20 Homo sapiens 8-12 15834625-6 2005 The short-term effect of PE and IVIgand the side effects associated with the long-term use of steroids have prompted the use of several IS, interferon and,more recently, the anti-CD20 monoclonal-antibody Rituximab, but their efficacy has still to be proved in controlled studies. Steroids 94-102 keratin 20 Homo sapiens 179-183 16095505-5 2005 The CD20-positive group was significantly more likely to have steroid-resistant rejection and reduced graft survival compared to CD20-negative controls. Steroids 62-69 keratin 20 Homo sapiens 4-8 12931119-1 2003 We reviewed the clinical outcome of 8 patients with steroid-refractory chronic graft-versus-host disease (GVHD) who received an anti-CD20 chimeric monoclonal antibody (rituximab). Steroids 52-59 keratin 20 Homo sapiens 133-137 11923690-5 2002 We present the case of a 50-year-old woman with hemodynamically significant humoral rejection resistant to steroids, cyclophos-phamide, and plasmapheresis who responded to the addition of anti-CD20 monoclonal antibody therapy (rituximab). Steroids 107-115 keratin 20 Homo sapiens 193-197 12819245-1 2003 Currently available monoclonal antibodies against the B cell surface antigen CD20 have been employed to explore whether specific inhibition of B cells may help improve the outcome of idiopathic membranous nephropathy (IMN) and may avoid the side effects of steroids and immunosuppressants. Steroids 257-265 keratin 20 Homo sapiens 77-81 34661744-1 2022 BACKGROUND: The therapeutic efficacy of B cell-depleting anti-CD20 treatment in both pediatric and adult steroid-sensitive nephrotic syndromes (SSNS) suggests that B cells play a pathogenic role in the disease. Steroids 105-112 keratin 20 Homo sapiens 62-66 33807051-4 2021 The CD20-binding antibody rituximab (RTX) appears a promising steroid-sparing therapy, although long-term data are lacking. Steroids 62-69 keratin 20 Homo sapiens 4-8 34544820-1 2021 BACKGROUND: The chimeric anti-CD20 monoclonal antibody rituximab is effective in steroid-dependent and calcineurin inhibitor-dependent forms of nephrotic syndrome, but many patients relapse at 1 year. Steroids 81-88 keratin 20 Homo sapiens 30-34 34132894-1 2022 BACKGROUND: Rituximab is a chimeric anti-CD20 monoclonal antibody that induces sustained remission in children with steroid-dependent nephrotic syndrome. Steroids 116-123 keratin 20 Homo sapiens 41-45 35240381-1 2022 The conventional treatment options (including alkylating agents, steroids, calcinurine inhibitors) have been largely replaced by anti-CD20 antibodies to achieve remission of nephrotic proteinuria in primary membranous nephropathy (PMN) patients. Steroids 65-73 keratin 20 Homo sapiens 134-138